Clinical Trials on Prostate Carcinoma in Argentina

Total 348 results

Inovio Pharmaceuticals

Completed

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (REVEAL 1)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Portugal, Italy, Philippines, Thailand, Slovakia, Lithuania, Estonia, Belgium, South Africa, Germany, Argentina, United Kingdom, Poland, Puerto Rico, Finland, Mexico, Peru
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, New Zealand
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
Eli Lilly and Company

Completed

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, France, Germany, Taiwan, Spain, Belgium, Switzerland, Netherlands, Russian Federation, South Africa, Poland, Hungary, Italy, Norway, India, Sweden, Argentina, United Kingdom, Puerto Rico, Chile, Romania
Basilea Pharmaceutica

Terminated

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)

Gastric Adenocarcinoma

Spain, United States, Korea, Republic of, Belgium, Russian Federation, United Kingdom, Italy, France, Turkey, Germany, Poland, Brazil, Australia, Argentina, Chile
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Exelixis

Active, not recruiting

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

Renal Cell Carcinoma

United States, Japan, Brazil, Argentina, Australia, Chile, Czechia, Germany, Greece, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Spain, Turkey, United Kingdom
Hoffmann-La Roche
Exelixis; Chugai

Active, not recruiting

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03)

Carcinoma, Renal Cell

United States, Korea, Republic of, France, Denmark, Italy, Poland, Spain, Japan, Canada, Argentina, United Kingdom, Russian Federation, Australia, Germany, Greece
Poniard Pharmaceuticals

Unknown

Study of Picoplatin Efficacy After Relapse (SPEAR)

Small Cell Lung Cancer

India, Russian Federation, Argentina, Belarus, Bosnia and Herzegovina, Bulgaria, Chile, Croatia, Hungary, Latvia, Montenegro, Poland, Romania, Serbia, Ukraine
Xcovery Holdings, Inc.

Active, not recruiting

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

Spain, United States, China, Korea, Republic of, Hong Kong, United Kingdom, Poland, Israel, Germany, France, Argentina, Australia, Brazil, Canada, Czechia, Italy, Netherlands, Russian Federation, Turkey, Belgium
Boehringer Ingelheim

Completed

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Bulgaria, Serbia, United Kingdom, United States, Korea, Republic of, Malaysia, Vietnam, Poland, Egypt, Hungary, Ukraine, Brazil, Turkey, Japan, Portugal, Thailand, Philippines, Russian Federation, Italy, Mexico, Greece, Croatia, Chi... and more
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Poland, Canada, Lithuania, Norway, Italy, Czechia
Pfizer

Completed

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Carcinoma, Pancreatic Ductal

United States, Netherlands, Canada, Hungary, Spain, United Kingdom, France, Austria, Belgium, Germany, Ireland, Korea, Republic of, Russian Federation, Sweden, South Africa, Italy, Singapore, Taiwan, Australia, India, Argentina, J... and more
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, Bulgaria, Czechia, Hu... and more
Genentech, Inc.

Completed

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Spain, France, United States, Taiwan, United Kingdom, Philippines, Latvia, Italy, Israel, Argentina, Mexico, Germany, Malaysia
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb; Parexel

Active, not recruiting

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Renal Cell Carcinoma

Canada, Italy, Spain, United States, United Kingdom, Australia, Germany, Poland, Belgium, Portugal, Czechia, Brazil, France, Argentina, Chile, Mexico
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

China, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS)

Non-Small Cell Lung Cancer

Canada, Belgium, Brazil, China, Denmark, Portugal, Spain, United Kingdom, Argentina, Bulgaria, Colombia, Germany, India, Ireland, Italy, Luxembourg, Mexico, Poland, Romania, Slovakia, Switzerland, Vietnam, Kazakhstan, Czechia
Novartis Pharmaceuticals

Terminated

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

Non-Small-Cell Lung

Germany, Spain, Belgium, Canada, Netherlands, Italy, Taiwan, Argentina, Australia, Israel, Japan, Lebanon, France, Poland, United States, Jordan, Korea, Republic of, China, Brazil, Czechia, Greece, Russian Federation, Denmark, Hungary, ... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

Carcinoma, Non-Small-Cell Lung

Canada, Germany, Italy, China, Belgium, United States, Taiwan, Israel, United Kingdom, Korea, Republic of, Sweden, Japan, Poland, Malaysia, Netherlands, Spain, Turkey, France, India, Mexico, Argentina, Brazil, Portugal, Russian Federation and more
Hoffmann-La Roche

Terminated

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Renal Cell Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Argentina, Australia, Belgium, Brazil, China, Denmark, Ireland, Spain, Japan, Netherlands, Chile, Czechia, Italy, France, Israel, Turkey, Germany, Austria, Taiwan, Serbia, Poland, Thailan... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

Carcinoma, Non-Small-Cell Lung

United States, France, Canada, China, Israel, Belgium, United Kingdom, Italy, Argentina, Japan, Taiwan, Thailand, Korea, Republic of, Malaysia, Poland, Australia, Spain, Netherlands, Hungary, Turkey, Germany, India, Brazil, Russian Federation and more
Bayer

Completed

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) (STORM)

Carcinoma, Hepatocellular

Belgium, France, Spain, China, Hong Kong, United States, Canada, Switzerland, Germany, Portugal, Taiwan, Japan, Russian Federation, Singapore, Austria, United Kingdom, Korea, Republic of, Australia, New Zealand, Mexico, Brazil, Italy and more
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Carcinoma, Non-Small-Cell Lung

Japan, China, Canada, Spain, Germany, Korea, Republic of, Austria, Brazil, Greece, France, United States, Italy, Argentina, Chile, Hungary, India, Turkey, Romania, Switzerland, Netherlands, Poland
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (VITAL)

Carcinoma | Non Small Cell Lung

United States, France, Canada, Brazil, Poland, Romania, Russian Federation, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Bulgaria, Estonia, India, Malaysia, Singapore, Taiwan, Czech Republic, Argentina, Finland, Hungary, Korea... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

Non-Small Cell Lung Cancer

China, Croatia, Taiwan, Greece, Canada, Thailand, Lebanon, Australia, Hong Kong, Romania, Slovenia, Spain, Jordan, Korea, Republic of, Serbia, Italy, Hungary, India, Turkey, Portugal, Argentina, Malaysia, Colombia, Denmark, Bulgaria, Iceland and more
Novartis Pharmaceuticals

Completed

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer (BASALT-1)

Non-small Cell Lung Cancer

France, Italy, United Kingdom, Hungary, Belgium, Canada, Spain, Germany, Singapore, Netherlands, Thailand, United States, Turkey, Argentina, Brazil, Hong Kong, Japan, Taiwan
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

Lung Cancer

France, Spain, Australia, United States, Sweden, Belgium, Switzerland, Italy, Egypt, South Africa, Israel, Colombia, Morocco, Norway, Greece, Brazil, Poland, Argentina, Austria, Chile, Czech Republic, Former Yugoslavia, Japan, Lithuania, Macedonia, The Former Yugoslav Republic... and more
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

China, Australia, United States, Turkey, Chile, Taiwan, Denmark, France, Spain, Argentina, Italy, Netherlands, Thailand, Korea, Republic of
Exelixis

Completed

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

Renal Cell Carcinoma

United States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150)

Carcinoma, Non-Small-Cell Lung

United States, Spain, France, Belgium, Australia, Germany, Argentina, Japan, Brazil, Italy, Singapore, Russian Federation, Taiwan, Netherlands, Peru, Chile, Latvia, Ukraine, Mexico, Lithuania, Slovakia, Bulgaria, Portugal, Austria, Swit... and more
Hoffmann-La Roche

Active, not recruiting

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms, Nerve... and other conditions

Italy, Korea, Republic of, Australia, Spain, Argentina, Belgium, Brazil, France, Portugal, United Kingdom, United States, Japan, Mexico, Poland, Norway, Costa Rica, Switzerland, Netherlands, Germany, Sweden, Turkey, Ireland, Panama
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
Bayer
Amgen

Completed

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Carcinoma, Renal Cell

Italy, Spain, Canada, United States, Russian Federation, France, Australia, Chile, Germany, Hungary, Israel, United Kingdom, South Africa, Poland, Netherlands, Belgium, Ukraine, Argentina, Brazil
Clovis Oncology, Inc.

Completed

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Metastatic Pancreatic Adenocarcinoma

United States, Belgium, Canada, Australia, United Kingdom, Germany, Italy, Argentina, Russian Federation, France, Brazil, Sweden, Norway, Netherlands, Ukraine
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Carcinoma, Non-Small-Cell Lung

United States, Ireland, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Carcinoma, Renal Cell

Canada, United States, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Spain, Swi... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Small Cell Lung Carcinoma

United States, Poland, Israel, Argentina, Australia, Austria, Canada, China, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, Portugal, Romania, Spain, Turkey, United...
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2)

Non-Small Cell Lung Cancer

United States, Spain, China, Italy, Turkey, Argentina, United Kingdom, Canada, Germany, Brazil, Vietnam, Thailand, Poland, Russian Federation, Japan, Korea, Republic of, Taiwan, Malaysia, Singapore, Romania
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Taiwan, Belgium, Denmark, Switzerland, Argentina, Israel, Italy, Croatia, United Kingdom, Korea, Republic of, Russian Federation, Slovakia, Japan, Bulgaria, Poland, Hungary, Australia, Turkey, Peru, Chile, Mexico, Czech... and more
Sabine Rhode
Ruhr University of Bochum

Unknown

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) (PIPACRegis)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Ascites | Pseudomyxoma Peritonei | Pancreas Cancer | Chemotherapeutic Toxicity | Pleural Effusion | Gallbladder Cancer | CUP | Appendix Cancer | Pleural Mesothelioma | Peritoneum Cancer | Peritoneum Neoplasm | Pleural Cancer

Singapore, France, Germany, Australia, Argentina, Austria, Belgium, Denmark, Italy, Poland, Russian Federation, Spain, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Renal Cell Carcinoma

United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, United Kingdom
Boehringer Ingelheim

Completed

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Carcinoma, Non-Small-Cell Lung

Germany, Canada, United States, Hong Kong, Taiwan, Brazil, Korea, Republic of, Peru, Poland, Ukraine, Thailand, Argentina, Australia, New Zealand, Sweden, Hungary, Turkey, Serbia, Bosnia and Herzegovina, Chile, Colombia, Ecuador, Ir... and more
Genentech, Inc.

Completed

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, France, Hungary, Australia, Brazil, Canada, Spain, Germany, United Kingdom, Chile, Israel, Italy, Netherlands, Argentina, Ukraine, Russian Federation
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Small Cell Lung Cancer

United States, Canada, Germany, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Czechia, India, Japan, Russian Federation, Turkey, China, United Kingdom, Argentina
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Japan, Mexico, Poland, Romania, Russian Federation, Spain, United Kingdom

Clinical Trials on Prostate Carcinoma in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations